Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Blood ; 114(11): 2299-306, 2009 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-19597182

RESUMEN

Therapeutic regulation of globin genes is a primary goal of translational research aimed toward hemoglobinopathies. Signal transduction was used to identify chromatin modifications and transcription factor expression patterns that are associated with globin gene regulation. Histone modification and transcriptome profiling were performed using adult primary CD34(+) cells cultured with cytokine combinations that produced low versus high levels of gamma-globin mRNA and fetal hemoglobin (HbF). Embryonic, fetal, and adult globin transcript and protein expression patterns were determined for comparison. Chromatin immunoprecipitation assays revealed RNA polymerase II occupancy and histone tail modifications consistent with transcriptional activation only in the high-HbF culture condition. Transcriptome profiling studies demonstrated reproducible changes in expression of nuclear transcription factors associated with high HbF. Among the 13 genes that demonstrated differential transcript levels, 8 demonstrated nuclear protein expression levels that were significantly changed by cytokine signal transduction. Five of the 8 genes are recognized regulators of erythropoiesis or globin genes (MAFF, ID2, HHEX, SOX6, and EGR1). Thus, cytokine-mediated signal transduction in adult erythroid cells causes significant changes in the pattern of globin gene and protein expression that are associated with distinct histone modifications as well as nuclear reprogramming of erythroid transcription factors.


Asunto(s)
Citocinas/metabolismo , Células Eritroides/metabolismo , Hemoglobina Fetal/biosíntesis , Histonas/metabolismo , Procesamiento Proteico-Postraduccional , Factores de Transcripción/metabolismo , Adulto , Antígenos CD34 , Células Cultivadas , Células Eritroides/citología , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Hemoglobinopatías/metabolismo , Humanos , ARN Polimerasa II/metabolismo , Transducción de Señal , Transcripción Genética
2.
Anaerobe ; 14(3): 166-71, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18396068

RESUMEN

Lactobacillus reuteri is a commensal-derived anaerobic probiotic that resides in the human gastrointestinal tract. L. reuteri converts glycerol into a potent broad-spectrum antimicrobial compound, reuterin, which inhibits the growth of gram-positive and gram-negative bacteria. In this study, we compared four human-derived L. reuteri isolates (ATCC 55730, ATCC PTA 6475, ATCC PTA 4659 and ATCC PTA 5289) in their ability to produce reuterin and to inhibit the growth of different enteric pathogens in vitro. Reuterin was produced by each of the four L. reuteri strains and assessed for biological activity. The minimum inhibitory concentration (MIC) of reuterin derived from each strain was determined for the following enteric pathogens: enterohemorrhagic Escherichia coli, enterotoxigenic E. coli, Salmonella enterica, Shigella sonnei and Vibrio cholerae. We also analyzed the relative abilities of L. reuteri to inhibit enteric pathogens in a pathogen overlay assay. The magnitude of reuterin production did not directly correlate with the relative ability of L. reuteri to suppress the proliferation of enteric pathogens. Additional antimicrobial factors may be produced by L. reuteri, and multiple factors may act synergistically with reuterin to inhibit enteric pathogens.


Asunto(s)
Gastroenteritis/microbiología , Gliceraldehído/análogos & derivados , Bacterias Gramnegativas/efectos de los fármacos , Intestinos/microbiología , Limosilactobacillus reuteri/metabolismo , Probióticos , Propano/farmacología , Antibiosis , Escherichia coli Enterohemorrágica/efectos de los fármacos , Escherichia coli Enterotoxigénica/efectos de los fármacos , Femenino , Gliceraldehído/metabolismo , Gliceraldehído/farmacología , Bacterias Gramnegativas/crecimiento & desarrollo , Bacterias Gramnegativas/patogenicidad , Humanos , Limosilactobacillus reuteri/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana , Propano/metabolismo , Salmonella enterica/efectos de los fármacos , Shigella sonnei/efectos de los fármacos , Vibrio cholerae/efectos de los fármacos
3.
Anesth Analg ; 100(5): 1303-1305, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15845673

RESUMEN

Many pediatric anesthesiologists divide acetaminophen suppositories to achieve an approximate dose. In this three-part study we first surveyed pediatric anesthesiologists regarding their attitudes and frequency of this clinical practice. Second, acetaminophen suppositories were divided for analysis of acetaminophen content. Finally, the accuracy of pediatric anesthesiologists in dividing suppositories was assessed. The survey indicated 50% of anesthesiologists believed acetaminophen was nonuniform and 62% believed the alteration of suppositories was inaccurate. The laboratory investigation revealed uniform distribution of acetaminophen but poor accuracy in achieving the target dose. The findings suggest using only intact suppositories for improved accuracy.


Asunto(s)
Acetaminofén/administración & dosificación , Analgésicos no Narcóticos/administración & dosificación , Acetaminofén/efectos adversos , Niño , Humanos , Hígado/efectos de los fármacos , Supositorios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA